WHAT IS THE OUTCOME OF PATIENTS WITH ACUTE LEUKEMIA WHO SURVIVE SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE?
(Abstract release date: 05/19/16)
EHA Library. Nagler A. 06/09/16; 133051; E1502
Prof. Arnon Nagler
Contributions
Contributions
Abstract
Abstract: E1502
Type: Eposter Presentation
Background
Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve in patients with severe acute GVHD.
Aims
We wanted to analyze the long-term outcome among patients who survive severe acute GVHD.
Methods
This is a landmark analysis of 23,567 patients with acute leukemia who survived >6 months after HSCT during 2002 – 2014. Patients with severe acute GVHD (n=1,738) were compared to controls.
Results
Patients with severe acute GVHD had a higher non-relapse mortality (NRM) and chronic GVHD compared to controls (p<10-5). Extensive chronic GVHD was 26.9% before 6 months and 27.2% after 6 months in the severe acute GVHD group (p<10-5). The probability of relapse was significantly lower in the severe acute GVHD group, and leukemia-free survival (LFS) and survival was significantly lower than for the controls (p<10-5). Five-year LFS in patients who survived severe acute GVHD was 49% as opposed to 61% in controls with no or mild, and 59% in patients with moderate GVHD.
Conclusion
HSCT patients who survive severe acute GVHD have a high risk of extensive chronic GVHD, a higher NRM, a lower relapse probability and lower LFS, compared to other HSCT patients.
Session topic: E-poster
Type: Eposter Presentation
Background
Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve in patients with severe acute GVHD.
Aims
We wanted to analyze the long-term outcome among patients who survive severe acute GVHD.
Methods
This is a landmark analysis of 23,567 patients with acute leukemia who survived >6 months after HSCT during 2002 – 2014. Patients with severe acute GVHD (n=1,738) were compared to controls.
Results
Patients with severe acute GVHD had a higher non-relapse mortality (NRM) and chronic GVHD compared to controls (p<10-5). Extensive chronic GVHD was 26.9% before 6 months and 27.2% after 6 months in the severe acute GVHD group (p<10-5). The probability of relapse was significantly lower in the severe acute GVHD group, and leukemia-free survival (LFS) and survival was significantly lower than for the controls (p<10-5). Five-year LFS in patients who survived severe acute GVHD was 49% as opposed to 61% in controls with no or mild, and 59% in patients with moderate GVHD.
Conclusion
HSCT patients who survive severe acute GVHD have a high risk of extensive chronic GVHD, a higher NRM, a lower relapse probability and lower LFS, compared to other HSCT patients.
Session topic: E-poster
Abstract: E1502
Type: Eposter Presentation
Background
Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve in patients with severe acute GVHD.
Aims
We wanted to analyze the long-term outcome among patients who survive severe acute GVHD.
Methods
This is a landmark analysis of 23,567 patients with acute leukemia who survived >6 months after HSCT during 2002 – 2014. Patients with severe acute GVHD (n=1,738) were compared to controls.
Results
Patients with severe acute GVHD had a higher non-relapse mortality (NRM) and chronic GVHD compared to controls (p<10-5). Extensive chronic GVHD was 26.9% before 6 months and 27.2% after 6 months in the severe acute GVHD group (p<10-5). The probability of relapse was significantly lower in the severe acute GVHD group, and leukemia-free survival (LFS) and survival was significantly lower than for the controls (p<10-5). Five-year LFS in patients who survived severe acute GVHD was 49% as opposed to 61% in controls with no or mild, and 59% in patients with moderate GVHD.
Conclusion
HSCT patients who survive severe acute GVHD have a high risk of extensive chronic GVHD, a higher NRM, a lower relapse probability and lower LFS, compared to other HSCT patients.
Session topic: E-poster
Type: Eposter Presentation
Background
Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve in patients with severe acute GVHD.
Aims
We wanted to analyze the long-term outcome among patients who survive severe acute GVHD.
Methods
This is a landmark analysis of 23,567 patients with acute leukemia who survived >6 months after HSCT during 2002 – 2014. Patients with severe acute GVHD (n=1,738) were compared to controls.
Results
Patients with severe acute GVHD had a higher non-relapse mortality (NRM) and chronic GVHD compared to controls (p<10-5). Extensive chronic GVHD was 26.9% before 6 months and 27.2% after 6 months in the severe acute GVHD group (p<10-5). The probability of relapse was significantly lower in the severe acute GVHD group, and leukemia-free survival (LFS) and survival was significantly lower than for the controls (p<10-5). Five-year LFS in patients who survived severe acute GVHD was 49% as opposed to 61% in controls with no or mild, and 59% in patients with moderate GVHD.
Conclusion
HSCT patients who survive severe acute GVHD have a high risk of extensive chronic GVHD, a higher NRM, a lower relapse probability and lower LFS, compared to other HSCT patients.
Session topic: E-poster
{{ help_message }}
{{filter}}